STOK (Stoke Therapeutics) Cash per Share : $4.01 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Stoke Therapeutics's Cash per Share for the quarter that ended in Dec. 2024 was $4.01.

Stoke Therapeutics Cash per Share Historical Data

The historical data trend for Stoke Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Cash per Share Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash per Share

Get a 7-Day Free Trial

7.86

5.96

5.82

4.39

4.01

Stoke Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash per Share	Get a 7-Day Free Trial															4.39	3.84	5.39	4.52	4.01

Stoke Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Stoke Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	216.899	/	54.03
	=	4.01

Stoke Therapeutics's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	216.899	/	54.03
	=	4.01

Stoke Therapeutics (NAS:STOK) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Stoke Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Executives

Jonathan Allan	officer: General Counsel & Corp Sec	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Kaye Edward M. Md	director, officer: CEO	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Barry Ticho	officer: Chief Medical Officer	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Skorpios Trust	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Huw M. Nash	officer: COO & CBO	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Stephen J Tulipano	officer: CFO	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Atp Life Science Ventures, L.p.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Montrago Trustees Ltd	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau	officer: EVP Research & Preclinical Dev	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin	director	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Arthur Tzianabos	director	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730